- Home
- MTEX vs NRSN Comparison
MTEX vs NRSN Comparison
Compare MTEX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- NRSN
- Stock Information
- Founded
- MTEX 1993
- NRSN 2017
- Country
- MTEX United States
- NRSN Israel
- Employees
- MTEX N/A
- NRSN N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- NRSN Health Care
- Exchange
- MTEX Nasdaq
- NRSN Nasdaq
- Market Cap
- MTEX 21.2M
- NRSN 17.8M
- IPO Year
- MTEX 1999
- NRSN 2021
- Fundamental
- Price
- MTEX $11.62
- NRSN $1.13
- Analyst Decision
- MTEX
- NRSN Hold
- Analyst Count
- MTEX 0
- NRSN 1
- Target Price
- MTEX N/A
- NRSN N/A
- AVG Volume (30 Days)
- MTEX 3.5K
- NRSN 113.6K
- Earning Date
- MTEX 03-27-2025
- NRSN 04-04-2025
- Dividend Yield
- MTEX N/A
- NRSN N/A
- EPS Growth
- MTEX N/A
- NRSN N/A
- EPS
- MTEX N/A
- NRSN N/A
- Revenue
- MTEX $121,552,000.00
- NRSN N/A
- Revenue This Year
- MTEX N/A
- NRSN N/A
- Revenue Next Year
- MTEX N/A
- NRSN N/A
- P/E Ratio
- MTEX N/A
- NRSN N/A
- Revenue Growth
- MTEX N/A
- NRSN N/A
- 52 Week Low
- MTEX $6.75
- NRSN $0.51
- 52 Week High
- MTEX $16.49
- NRSN $2.25
- Technical
- Relative Strength Index (RSI)
- MTEX 52.44
- NRSN 52.05
- Support Level
- MTEX $10.80
- NRSN $1.02
- Resistance Level
- MTEX $11.90
- NRSN $1.20
- Average True Range (ATR)
- MTEX 0.53
- NRSN 0.08
- MACD
- MTEX 0.07
- NRSN 0.00
- Stochastic Oscillator
- MTEX 77.24
- NRSN 49.07
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.